Literature DB >> 29558272

Severity of Pain and Sleep Problems during Kratom (Mitragyna speciosa Korth.) Cessation among Regular Kratom Users.

Darshan Singh1, Suresh Narayanan2, Balasingam K Vicknasingam1, Walter C Prozialeck3, Surash Ramanathan1, Hadzliana Zainal4, Sabariah Noor Harun4.   

Abstract

Kratom (Mitragyna speciosa Korth.) is traditionally used in Southeast Asia for its medicinal value and psychoactive properties. Nonetheless, cessation from regular kratom use is reported to cause unpleasant dose-dependent withdrawal symptoms. This study aims to evaluate the severity of pain and sleep problems following the cessation of kratom tea/juice consumption among regular kratom users. A total of 170 regular users were recruited through snowball sampling for this cross-sectional study. The Brief Pain Inventory (BPI) and Pittsburgh Sleep Quality Index (PSQI) scales were administered to assess the severity of pain and sleep problems. Most participants experienced moderate pain intensity (84%) and moderate pain interference (70%) during kratom cessation; 46% experienced more sleep problems during kratom cessation. Individuals who consumed ≥4 glasses of kratom tea/juice (about 76-115 mg of mitragynine) daily had higher odds of reporting some pain interference (OR: 2.0; CI: 1.04-3.93: p < .028), and sleep problems during kratom cessation (OR: 2.0; CI: 1.08-3.68: p < .020), as compared to those who consumed 1-3 glasses of kratom tea/juice daily. However, the effects were still relatively mild. Cessation from regular kratom tea/juice consumption is not associated with prolonged pain and sleep problems, as compared to those reported for opioid analgesics.

Entities:  

Keywords:  Kratom; Malaysia; mitragyna speciosa; pain; sleep problems

Mesh:

Substances:

Year:  2018        PMID: 29558272     DOI: 10.1080/02791072.2018.1443234

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  5 in total

Review 1.  [Kratom - a short review for pain medicine].

Authors:  Florian Lautenschlager; Manfred Weiss; Sigrun Feuerer; Norbert Wodarz
Journal:  Schmerz       Date:  2021-09-17       Impact factor: 1.629

2.  Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study.

Authors:  Antonio Metastasio; Elisabeth Prevete; Darshan Singh; Oliver Grundmann; Walter C Prozialeck; Charles Veltri; Giuseppe Bersani; Ornella Corazza
Journal:  Front Psychiatry       Date:  2020-11-19       Impact factor: 4.157

3.  Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant.

Authors:  Alessandro E Vento; Simone de Persis; Sergio De Filippis; Fabrizio Schifano; Flavia Napoletano; John M Corkery; Georgios D Kotzalidis
Journal:  Front Psychiatry       Date:  2021-03-31       Impact factor: 4.157

Review 4.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

5.  Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats.

Authors:  Rahimah Hassan; Sasidharan Sreenivasan; Christian P Müller; Zurina Hassan
Journal:  Front Pharmacol       Date:  2021-07-12       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.